VBIVQ — VBI Vaccines Income Statement
0.000.00%
Last trade - 00:00- $0.01m
- $36.16m
- $8.68m
Annual income statement for VBI Vaccines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.22 | 1.06 | 0.631 | 1.08 | 8.68 |
| Cost of Revenue | |||||
| Gross Profit | -5.68 | -8.11 | -10.1 | -10.2 | -3.83 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 54.6 | 44.7 | 68.7 | 83.1 | 88.6 |
| Operating Profit | -52.4 | -43.6 | -68 | -82 | -79.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -54.8 | -46.2 | -69.8 | -113 | -92.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -54.8 | -46.2 | -69.8 | -113 | -92.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -54.8 | -46.2 | -69.8 | -113 | -92.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -54.8 | -46.2 | -69.8 | -113 | -93.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -12.2 | -6.35 | -8.21 | -13.1 | -4.45 |